Shares of Radius Health took a nosedive on Thursday after the Waltham biotech revealed early-stage data on a breast cancer drug showing partial responses by a relatively small number of patients. Radius Health CEO Robert Ward previously said during a Nov. 3 earnings call that the company had observed “multiple confirmed clinical responses” during two ongoing Phase 1 studies of the treatment, called RAD1901.